Skip to main content
Fig. 2 | Trials

Fig. 2

From: The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor

Fig. 2

Explanation of PFS endpoints. *After patients randomised to the CD arm reach disease progression, they are given the option to switch to ICD treatment until they disease progress a second time. Patients randomised to the ICD arm that reach disease progression will be followed-up but treated off-trial as per standard practice

Back to article page

Trials

ISSN: 1745-6215